Scholarships for stem-cell research News-Medical-Net Tue, 24 Jun 2008 9:16 PM PDT The NSW Government has named two new scholarships for stem-cell research in honour of Paul Brock, an adjunct professor at the University of Sydney and a leading figure in Australia's education community. | Comprehensive Stem Cell Storage And Processing Facility Opening In China BioresearchOnline Tue, 24 Jun 2008 7:32 AM PDT Shenzhen Beike Biotechnology Co., Ltd., a worldwide leader in providing safe and effective stem cell applications for medical treatment, has commenced outfitting its 21,500 square foot comprehensive medical stem cell storage and processing facility in eastern China | Stem cell treatment in clinical trial at Texas Heart Institute Friendswood Journal Tue, 24 Jun 2008 11:26 AM PDT Physician scientists at the Texas Heart Institute (THI) at St. Luke's Episcopal Hospital announced they have begun the world's first clinical trial to treat heart attack patients with a special type of stem cell to promote better healing and to prevent congestive heart failure, which many patients develop following a heart attack.... | New stem cells can regenerate heart tissue Moldova.org Tue, 24 Jun 2008 11:33 AM PDT U.S. scientists say they've identified a new group of stem cells that can create cardiomyocytes, or heart muscle cells, to regenerate injured heart tissue.The finding by researchers at Children's Hospital Boston follows studies that found a specific stem cell or progenitor, marked by expression of a gene called Nkx2-5 can form many components of the heart, including heart muscle cells.In the new ... | EyeCyte secures Series A funding from Pfizer Pharmaceutical Business Review Tue, 24 Jun 2008 5:54 PM PDT EyeCyte, an early stage stem/progenitor cell-based ophthalmology R&D company, has secured its Series A funding through an agreement with Pfizer. | EyeCyte, Inc. Secures Series A Funding From Pfizer Medical News Today Tue, 24 Jun 2008 6:19 AM PDT EyeCyte, Inc., an early stage stem/progenitor cell-based ophthalmology research and development company based in La Jolla, California, announced that it has secured its Series A funding through an agreement with Pfizer. The financing will fund the company into 2010 and will be primarily used to drive product development of the company's initial clinical target, diabetic retinopathy. | Pfizer buys into biotech working on eye disease New London Day Tue, 24 Jun 2008 3:22 AM PDT Pfizer Inc. announced Monday that it is funding a new San Diego biotech company that will test novel stem-cell treatments for use in fighting eye | | |
|